Download PDF
Thromb Haemost 2005; 94(06): 1327-1328
DOI: 10.1160/TH05-06-1327
Case Report
Schattauer GmbH

Angiographic documentation of the efficacy of recombinant activated factor VII (NovoSeven) to control diffuse bleeding in major trauma

Bart Van Der Schueren
1   Haemostasis and Thrombosis Unit, 1Department of Haematology
,
Frank Hammer
2   Department of Radiology and Diagnostic Imaging, Emergency and
,
Franck Verschuren
3   Intensive Care Department, Haemostasis Laboratory
,
Philippe Hantson
3   Intensive Care Department, Haemostasis Laboratory
,
Véronique Deneys
4   Department of Biological Chemistry, Cliniques Universitaires Saint-Luc, Catholic University of Louvain, Brussels, Belgium
,
Cedric Hermans
1   Haemostasis and Thrombosis Unit, 1Department of Haematology
› Author Affiliations
Further Information

Publication History

Received 03 March 2005

Accepted after resubmission 14 September 2005

Publication Date:
07 December 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Kenet G, Walden R, Eldad A. et al Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999; 354: 1879.
    CrossrefPubMedSearch in Google Scholar
  • 2 Goodnough LT, Lublin DM, Zhang L. et al Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion 2004; 44: 1325-31.
    CrossrefPubMedSearch in Google Scholar
  • 3 Grounds M. Recombinant factor VIIa (rFVIIa) and its use in severe bleeding in surgery and trauma: a review. Blood Rev 2003; 17: S11-21.
    CrossrefPubMedSearch in Google Scholar
  • 4 Dutton RP, McCunn M, Hyder M. et al Factor VIIa for correction of traumatic coagulopathy. J Trauma 2004; 57: 709-19.
    CrossrefPubMedSearch in Google Scholar
  • 5 Eikelboom JW, Bird R, Blythe D. et al Recombinant activated factor VII for the treatment of lifethreatening haemorrhage. Blood Coagul Fibrinolysis 2003; 14: 713-7.
    CrossrefPubMedSearch in Google Scholar
  • 6 Boffard KD, Riou B, Warren B. et al NovoSeven Trauma Study Group. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 2005; 59: 8-15 discussion 15–8.
    CrossrefPubMedSearch in Google Scholar
  • 7 Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 2005; 33: 883-90.
    CrossrefPubMedSearch in Google Scholar
  • 8 Ahonen J, Jokela R. Recombinant factor VIIa for life-threatening post-partum haemorrhage. Br J Anaesth 2005; 94: 592-5.
    CrossrefPubMedSearch in Google Scholar
  • 9 Goodnough LT, Lublin DM, Zhang L. et al Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion 2004; 44: 1325-31.
    CrossrefPubMedSearch in Google Scholar
  • 10 Martinowitz U, Michaelson M. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost 2005; 3: 640-8.
    CrossrefPubMedSearch in Google Scholar